AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
GT Biopharma expands private placement to $8.61M stated value with greenshoe option up to $34.7M.
PUBLIC · GTBPSep 21, 2026•about 4 hours ago
Amount Raised
$300,000
Round Type
Seed
San FranciscoBiotechnology
Description
GT Biopharma expanded its Series M private placement of 10% Convertible Preferred Stock and warrants, increasing the stated value to $8.61 million for a $7.75 million purchase price. The amendment introduced purchaser greenshoe rights of up to $34.68 million in stated value and added a new investor. The company initially launched the placement on September 14, 2026, with an $8.28 million stated value for $7.45 million. The transactions strengthen liquidity and support corporate initiatives.
Company Information
Company
GT Biopharma
Location
505 MONTGOMERY STREET
San Francisco, California, United States
About
GT Biopharma is a biotechnology company developing novel immuno-oncology biopharmaceutical drugs using its proprietary NK cell engager (TriKE) platform technology. By leveraging this innovative approach, GT Biopharma is targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors. Traded on NASDAQ under GTBP, the company is committed to advancing cutting-edge therapies that harness the power of the immune system to fight cancer.
Fundz sees it the moment GT Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San FranciscoBiotechnology